Experimental drug eliminates 75% of aggressive pancreatic tumors and enhances immune system memory

Key Points:

• Researchers have developed an experimental drug, FEBP-sTβRII, that targets and breaks down the dense fibrous tissue barrier in solid tumors, allowing cancer-killing T cells to infiltrate and attack tumors effectively.
• The drug selectively binds to fibronectin abundant in tumors, minimizing side effects by concentrating its action within the tumor environment, and has shown promising results in mouse models of pancreatic, breast, and other cancers.
• In treated mice, the drug not only eradicated aggressive tumors and prevented metastasis but also induced long-lasting immune memory that protected against tumor recurrence and even different cancer types.
• Combining FEBP-sTβRII with existing immunotherapy (anti-PD-1) enhanced treatment efficacy, nearly eradicating resistant pancreatic tumors, highlighting its potential to improve outcomes in tumors unresponsive to current therapies.
• A human version of the drug is undergoing safety testing, with clinical trials planned for 2027 to evaluate its effectiveness in patients with solid tumors resistant to standard treatments.